Cholangiocarcinoma (CCA) is a rare and aggressive cancer originating in the bile ducts, which transport bile from the liver to the digestive system. It is classified into intrahepatic, perihilar, and distal types based on its location. Symptoms often include jaundice, abdominal pain, fatigue, and unexplained weight loss. Risk factors include chronic biliary inflammation, primary sclerosing cholangitis, liver fluke infections, and exposure to toxins. Cholangiocarcinoma is typically diagnosed late due to its subtle early symptoms, making prognosis challenging. Cholangiocarcinoma pipeline analysis by Expert Market Research highlights promising drug candidates, including small molecules, gene therapies, and monoclonal antibodies.
Major companies involved in the cholangiocarcinoma pipeline analysis include Eli Lilly and Company, Incyte Corporation and Seagen.
Leading drugs currently under the pipeline include LY3410738 and pemigatinib, among others.
The increasing cases of cholangiocarcinoma and the rising technological advancements are poised to positively influence the cholangiocarcinoma pipeline landscape.
The Cholangiocarcinoma Pipeline Analysis Report by Expert Market Research gives comprehensive insights into cholangiocarcinoma therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for cholangiocarcinoma. The cholangiocarcinoma report assessment includes the analysis of over 25 pipeline drugs and 10+ companies. The cholangiocarcinoma pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials including their adverse effects on patients suffering from the condition, and alignment with cholangiocarcinoma treatment guidelines to ensure optimal care practices.
The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to cholangiocarcinoma.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Chronic inflammation and cholestasis, frequently brought on by diseases like primary sclerosing cholangitis or liver fluke infections, cause biliary epithelial cells to malignantly convert into cholangiocarcinoma. Prolonged inflammation promotes unregulated proliferation and survival by causing DNA damage, epigenetic modifications, and deregulation of carcinogenic pathways such EGFR/ERB-B2 and IL-6/STAT3. Carcinogenesis is further fueled by genetic alterations (KRAS, IDH1/2, TP53), but autocrine/paracrine signaling is maintained by cytokines and growth hormones (e.g., hepatocyte growth factor). Desmoplastic stroma and cancer-associated fibroblasts are characteristics of the tumor microenvironment that promote invasion and metastasis. Adenocarcinomas with aggressive local infiltration account for most cases (>90%).
Surgery for isolated tumors is the main treatment for cholangiocarcinoma, with the goal of removing as much cancer as possible. Chemotherapy is the mainstay of palliative care for cases that cannot be cured. The first-line treatment is cisplatin plus gemcitabine, which has been demonstrated to increase overall survival when compared to gemcitabine alone. Additionally, targeted medicines that target genetic abnormalities within cancers are becoming more popular. Clinical trials are still investigating novel approaches to improve the treatment of this difficult cancer type.
The prevalence of cholangiocarcinoma (CCA), which currently makes up 15% of primary liver tumors and roughly 3% of gastrointestinal cancers, is rising worldwide. Although incidence rates differ greatly by area, about 8,000 new cases are detected in the US each year. In Hong Kong, for example, the rate of intrahepatic cholangiocarcinoma (ICC) is 2.3 per 100,000, while in Argentina it is 0.14 per 100,000. All things considered, improved diagnostic procedures and a greater awareness of risk factors are responsible for the rising trends in ICC and extrahepatic cholangiocarcinoma (ECC).
This section of the report covers the analysis of cholangiocarcinoma drug candidates based on several segmentations including:
By Phase
By Drug Class
By Route of Administration
The report covers phase I, phase II, phase III, phase IV, and early phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase III covers a major share of the total clinical trials, with a substantial number of cholangiocarcinoma drugs undergoing clinical development.
The drug molecule categories covered under cholangiocarcinoma pipeline analysis include small molecules, biologics, peptides, and immunotherapies, among others. The cholangiocarcinoma report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for cholangiocarcinoma.
The EMR report for the cholangiocarcinoma pipeline covers the profile of key companies involved in clinical trials and their drugs under development. It provides a detailed cholangiocarcinoma therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is the list of a few players involved in cholangiocarcinoma clinical trials:
This section covers the detailed analysis of each drug under multiple phases, including phase I, phase II, phase III, phase IV, and emerging drugs for cholangiocarcinoma. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of cholangiocarcinoma drug candidates.
LY3410738 is an investigational, oral, covalent inhibitor targeting mutant isocitrate dehydrogenase (IDH) 1 and 2 enzymes, developed by Eli Lilly and Company. It is designed to bind irreversibly to mutant IDH1, blocking the production of the oncometabolite (R)-2-hydroxyglutarate ((R)-2HG), which is implicated in various cancers. LY3410738 is currently in Phase 1 of clinical trials to evaluate its safety, tolerability, and efficacy in patients with advanced solid tumors and hematologic malignancies harboring IDH1 or IDH2 mutations.
Pemigatinib, is a selective fibroblast growth factor receptor (FGFR) inhibitor developed by Incyte Corporation. It received accelerated FDA approval in 2020 for treating adults with previously treated unresectable locally advanced or metastatic cholangiocarcinoma harboring FGFR2 fusions or rearrangements. The approval was based on the FIGHT-202 Phase 2 study, which demonstrated an overall response rate of 35.5% in patients with FGFR2 fusions. Pemigatinib is currently in Phase 3 clinical trials to further evaluate its safety and efficacy in treating cholangiocarcinoma and other FGFR-related malignancies.
*Please note that this is only a partial list; the complete list of drugs will be available in the full report.*
The Cholangiocarcinoma Pipeline Analysis Report provides a strategic overview of the latest and future landscape of treatments for cholangiocarcinoma. it provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into market trends, regulatory environments, and potential growth opportunities within the cholangiocarcinoma pipeline insights.
Cholangiocarcinoma (CCA) Epidemiology Forecast
Upto 15% Off
USD
$1999 $1799
$3099 $2789
$4599 $3909
$5999 $5099
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
|
Scope of the Report |
Details |
|
Drug Pipeline by Clinical Trial Phase |
|
|
Route of Administration |
|
|
Drug Classes |
|
|
Leading Sponsors Covered |
|
|
Geographies Covered |
|
Mini Report
One User
USD 1,999
USD 1,799
tax inclusive*
Single User License
One User
USD 3,099
USD 2,789
tax inclusive*
Five User License
Five User
USD 4,599
USD 3,909
tax inclusive*
Corporate License
Unlimited Users
USD 5,999
USD 5,099
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Share